Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Astellas Pharma Global Development, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer

Phase 1

Recruiting

Conditions: Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: zolbetuximab
Drug: mFOLFIRINOX

First Posted Date: 2024-05-02

Last Posted Date: 2025-05-22

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 12

Registration Number: NCT06396091

Locations: 🇺🇸
Johns Hopkins Hospital, Washington, District of Columbia, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Providence Medical Foundation, Fullerton, California, United States

and more 4 locations

A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas

Phase 1

Terminated

Conditions: B-cell Lymphoma

Interventions: Drug: ASP2802
Drug: MA-20

First Posted Date: 2024-02-08

Last Posted Date: 2025-01-06

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 1

Registration Number: NCT06248086

Locations: 🇦🇺
Site AU61004, Sydney, Australia

A Study of ASP1012 in Adults With Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: ASP1012
Drug: Pembrolizumab

First Posted Date: 2023-12-14

Last Posted Date: 2025-06-22

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 229

Registration Number: NCT06171178

Locations: 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States

and more 6 locations

A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

Active, not recruiting

Conditions: Hot Flashes

Interventions: Drug: Fezolinetant
Drug: Paroxetine
Drug: Gabapentin
Drug: Citalopram
Drug: Clonidine
Drug: Pregabalin
Drug: Escitalopram
Drug: Desvenlafaxine
Drug: Oxybutynin
Drug: Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above
Drug: Venlafaxine
Drug: Any other SSRI/SNRI not already specified

First Posted Date: 2023-09-22

Last Posted Date: 2025-06-11

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 1003

Registration Number: NCT06049797

Locations: 🇺🇸
Alabama Clinical Therapeutics, Birmingham, Alabama, United States
🇺🇸
Accel Research Sites-Cahaba Medical Care-OBGYN, Birmingham, Alabama, United States
🇺🇸
Precision Trials AZ, LLC, Phoenix, Arizona, United States

and more 46 locations

Early Access Program for Zolbetuximab

Conditions: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer
Locally Advanced Unresectable Gastric Adenocarcinoma Cancer
Metastatic Gastric Adenocarcinoma Cancer
Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

First Posted Date: 2023-09-21

Last Posted Date: 2025-04-01

Lead Sponsor: Astellas Pharma Global Development, Inc.

Registration Number: NCT06048081

Locations: 🇧🇷
BR55009, Belem, Brazil
🇧🇷
BR55001, Belo Horizonte, Brazil
🇧🇷
BR55004, Brasília, Brazil

and more 88 locations

A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney Disease

Phase 3

Recruiting

Conditions: Intraoperative Ureter Visualization
Abdominolpelvic Surgery

Interventions: Drug: pudexacianinium chloride

First Posted Date: 2023-08-21

Last Posted Date: 2025-06-25

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 94

Registration Number: NCT05999747

Locations: 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸
Cleveland Clinic Florida, Weston, Florida, United States

and more 7 locations

A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease

Phase 3

Recruiting

Conditions: Chronic Kidney Disease
Renal Anemia

Interventions: Drug: Roxadustat

First Posted Date: 2023-08-01

Last Posted Date: 2025-06-25

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 100

Registration Number: NCT05970172

Locations: 🇹🇷
Site TR90007, Ankara, Turkey
🇧🇪
Site BE32002, Brussels, Belgium
🇧🇪
Site BE32001, Edegem, Belgium

and more 40 locations

A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery

Phase 3

Completed

Conditions: Abdominolpelvic Surgery
Intraoperative Ureter Visualization

Interventions: Drug: pudexacianinium chloride

First Posted Date: 2023-03-03

Last Posted Date: 2025-01-30

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 107

Registration Number: NCT05754333

Locations: 🇺🇸
AdventHealth Orlando, Orlando, Florida, United States
🇺🇸
Advent Health Tampa, Tampa, Florida, United States
🇺🇸
Cleveland Clinic Florida, Weston, Florida, United States

and more 3 locations

A Study of ASP1002 in Adults for Treatment of Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: ASP1002

First Posted Date: 2023-02-09

Last Posted Date: 2025-07-01

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 210

Registration Number: NCT05719558

Locations: 🇺🇸
Swedish Cancer Institute, Edmonds, Washington, United States
🇺🇸
Yale University Cancer Center, New Haven, Connecticut, United States
🇺🇸
Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut, Plainville, Connecticut, United States

and more 12 locations

A Study of ASP2074 in Adults With Solid Tumors

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Drug: ASP2074

First Posted Date: 2022-12-12

Last Posted Date: 2025-04-06

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 23

Registration Number: NCT05646797

Locations: 🇺🇸
University of California Davis Health System, Sacramento, California, United States
🇺🇸
University of Iowa Hospitals, Iowa City, Iowa, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy